Abstract
Purpose. To evaluate the potential of several bis-ester prodrugs of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine (PMEA, adefovir) to enhance the oral absorption of PMEA.
Methods. Caco-2 monolayers were used to estimate intestinal transport and metabolism of the bis(pivaloyloxymethyl)-ester [bis(POM)-] and a series of bis(S-acyl-2-thioethyl)-esters [bis(SATE)-] of PMEA. An LC-MS method was used for the identification of unknown metabolites which were formed from the SATE-esters.
Results. During transport across Caco-2 monolayers, all esters were extensively degraded as could be concluded from the appearance of the mono-ester and free PMEA in apical as well as basolateral compartments. Incubation of SATE-esters with the monolayers resulted in the formation of two additional metabolites, which were identified as 2-thioethyl-PMEA and its dimerisation product. All ester prodrugs resulted in enhanced transepithelial transport of total PMEA (i.e. the bis-esters and their corresponding metabolites, including PMEA), but significant differences could be observed between the various esters. Transport of total PMEA ranged from 0.4 ± 0.1 % for the bis[S(methyl) ATE]-ester to 15.3 ± 0.9% for the more lipophilic bis[S(phenyl)ATE]-PMEA. A relationship between total transport of the esters and their lipophilicity (as estimated by their octanol/water partition coefficient) was established (r2 = 0.87). Incubation of prodrug esters with homogenates from Caco-2 cells showed large differences in susceptibility of the compounds to esterases, the half-lives of the bis-esters varying from 4.3 ± 0.3 min for the bis[S(phenyl)ATE]-PMEA to 41.5 ± 0.8 min for its methyl analogue. In addition, intracellularly formed PMEA was observed to be further converted by the cells to the diphosphorylated PMEA (PMEApp).
Conclusions. Several SATE-esters of PMEA can be considered as potential alternatives to bis(POM)-PMEA, due to enhanced epithelial transport, sufficient chemical and enzymatic stability and adequate release of PMEA. Toxicological studies as well as in vivo experiments are required in order to further explore the potential of those SATE-esters as prodrugs for oral delivery of PMEA.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
L. Naesens, J. Balzarini, N. Bischofberger, and E. De Clercq. Antimicrob. Agents Chemother. 40:22–28 (1996).
L. Naesens, R. Snoeck, G. Andrei, J. Balzarini, J. Neyts, and E. de Clercq. Antiviral Chem. Chemother. 8:1–23 (1997).
K. C. Cundy, J. A. Fishback, J.-P. Shaw, M. L. Lee, K. F. Soike, G. C. Visor, and W. A. Lee. Pharm. Res. 11:839–843 (1994).
J. Balzarini, L. Naesens, J. Slachmuylders, H. Niphuis, I. Rosenberg, A. Holý, H. Schellekens, and E. De Clercq. AIDS 5:21–28 (1991).
K. C. Cundy and W. A. Lee. Antimicrobs. Agents Chemother. 38:365–368 (1994).
J. E. Starrett, Jr., D. R. Tortolani, J. Russell, M. J. M. Hitchcock, V. Whiterock, J. C. Martin, and M. M. Mansuri. J. Med. Chem. 37:1857–1864 (1994).
J.-P. Shaw and K. C. Cundy. Pharm. Res. 10(Suppl.):S294 (1993).
P. Artursson. J. Pharm. Sci. 79(6):476–482 (1990).
K. L. Audus, R. L. Bartel, I. J. Hildago, and R. T. Borchardt. Pharm. Res. 7:435–451 (1990).
A. R. Hilgers, R. A. Conradi, and P. S. Burton. Pharm. Res. 7:902–910 (1990).
L. S. Gan, C. Eads, T. Niederer, A. Bridgers, S. Yanni, P.-H. Hsyu, F. J. Pritchard, and D. Thakker. Drug Develop. Ind. Pharm. 20:615–631 (1994).
P. Annaert, R. Kinget, L. Naesens, E. De Clercq, and P. Augustijns. Pharm. Res. 14:492–496 (1997).
P. A. Barditch-Crovo, K. C. Cundy, M. Wachsman, J. Toole, H. Burgee, and D. Ebeling. Antiviral Res. 26(3, suppl.):A229, abstract nr. 9 (1995).
S. Benzaria, H. Pélicano, R. Johnson, G. Maury, J.-L. Imbach, A.-M. Aubertin, G. Obert, and G. Gosselin. J. Med. Chem. 39:4958–4965 (1996).
G. Valette, A. Pompon, J.-L. Girardet, L. Cappellacci, P. Franchetti, M. Grifantini, P. La Colla, A.-G. Loi, C. Périgaud, G. Gosselin, and J.-L. Imbach. J. Med. Chem. 39:1981–1990 (1996).
S. Hatse, E. De Clercq, and J. Balzarini. Mol. Pharmacol. 50:1231–1242 (1996).
O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall. J. Biol. Chem. 193:265–275 (1951).
A. Pompon I. Lefebvre, J.-L. Imbach, S. Kahn, and D. Farquhar. Antiviral Chem. Chemother. 5:91–98 (1994).
D. Farquhar, S. Khan, D. N. Srivasta, and P. P. Saunders. J. Med. Chem. 37:3902–3909 (1994).
I. Lefebvre, C. Périgaud, A. Pompon, A.-M. Aubertin, J.-L. Girardet, A. Kirn, G. Gosselin, and J.-L. Imbach. J. Med. Chem. 38:3941–3950 (1995).
N. M. Nielsen and H. Bundgaard. Int. J. Pharm. 39:75–85 (1987).
A. Durrer, B. Walther, A. Racciatti, G. Boss, and B. Testa. Pharm. Res. 8:832–839 (1991).
I. J. Hildago, T. J. Raub, and R. T. Borchardt. Gastroenterology 96:736–49 (1989).
A. Merta, I. Votruba, J. Jindrich, A. Holy, T. Cihlar, I. Rosenberg, M. Otmar, and T. Y. Herve. Biochem. Pharmacol. 44:2067–2077 (1992).
J. Balzarini and E. De Clercq. J. Biol. Chem. 266:8686–8689 (1991).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Annaert, P., Gosselin, G., Pompon, A. et al. Comparison of the Disposition of Ester Prodrugs of the Antiviral Agent 9-(2-phosphonylmethoxyethyl)adenine [PMEA] in Caco-2 Monolayers. Pharm Res 15, 239–245 (1998). https://doi.org/10.1023/A:1011914618109
Issue Date:
DOI: https://doi.org/10.1023/A:1011914618109